Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review
dc.contributor.author | El Alayli, Abdallah | |
dc.contributor.author | Brignardello Petersen, Romina | |
dc.contributor.author | Husainat, Nedaa M. | |
dc.contributor.author | Kalot, Mohamad A. | |
dc.contributor.author | Aljabiri, Yazan | |
dc.contributor.author | Turkmani, Hani | |
dc.contributor.author | Britt, Alec | |
dc.contributor.author | El-Khechen, Hussein | |
dc.contributor.author | Shahid, Shaneela | |
dc.contributor.author | Roller, John | |
dc.contributor.author | Motaghi, Shahrzad | |
dc.contributor.author | Mansour, Razan | |
dc.contributor.author | Tosetto, Alberto | |
dc.contributor.author | Abdul-Kadir, Rezan | |
dc.contributor.author | Laffan, Michael | |
dc.contributor.author | Weyand, Angela | |
dc.contributor.author | Leebeek, Frank W.G. | |
dc.contributor.author | Arapshian, Alice | |
dc.contributor.author | Kouides, Peter | |
dc.contributor.author | James, Paula | |
dc.contributor.author | Connell, Nathan T. | |
dc.contributor.author | Flood, Veronica H. | |
dc.contributor.author | Mustafa, Reem A. | |
dc.date.accessioned | 2022-06-01T20:29:22Z | |
dc.date.available | 2023-06-01 16:29:20 | en |
dc.date.available | 2022-06-01T20:29:22Z | |
dc.date.issued | 2022-05 | |
dc.identifier.citation | El Alayli, Abdallah; Brignardello Petersen, Romina; Husainat, Nedaa M.; Kalot, Mohamad A.; Aljabiri, Yazan; Turkmani, Hani; Britt, Alec; El-Khechen, Hussein ; Shahid, Shaneela; Roller, John; Motaghi, Shahrzad; Mansour, Razan; Tosetto, Alberto; Abdul-Kadir, Rezan ; Laffan, Michael; Weyand, Angela; Leebeek, Frank W.G.; Arapshian, Alice; Kouides, Peter; James, Paula; Connell, Nathan T.; Flood, Veronica H.; Mustafa, Reem A. (2022). "Outcomes of long- term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review." Haemophilia 28(3): 373-387. | |
dc.identifier.issn | 1351-8216 | |
dc.identifier.issn | 1365-2516 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/172819 | |
dc.description.abstract | BackgroundVon Willebrand Disease (VWD) is a common inherited bleeding disorder. Patients with VWD suffering from severe bleeding may benefit from the use of secondary long-term prophylaxis.AimSystematically summarize the evidence on the clinical outcomes of secondary long-term prophylaxis in patients with VWD and severe recurrent bleedings.MethodsWe searched Medline and EMBASE through October 2019 for relevant randomized clinical trials (RCTs) and comparative observational studies (OS) assessing the effects of secondary long-term prophylaxis in patients with VWD. We used Cochrane Risk of Bias (RoB) tool and the RoB for Non-Randomized Studies of interventions (ROBINS-I) tool to assess the quality of the included studies. We conducted random-effects meta-analyses and assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.ResultsWe included 12 studies. Evidence from one placebo controlled RCT suggested that VWD prophylaxis as compared to no prophylaxis reduced the rate of bleeding episodes (Rate ratio [RR], .24; 95% confidence interval [CI], .17–.35; low certainty evidence), and of epistaxis (RR, .38; 95%CI, .21–.67; moderate certainty evidence), and may increase serious adverse events RR 2.73 (95%CI .12–59.57; low certainty). Evidence from four before-and-after studies in which researchers reported comparative data suggested that VWD prophylaxis reduced the rate of bleeding (RR .34; 95%CI, .25–.46; very low certainty evidence).ConclusionVWD prophylaxis treatment seems to reduce the risk of spontaneous bleeding, epistaxis, and hospitalizations. More RCTs should be conducted to increase the certainty in these benefits. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | bleeding disorder | |
dc.subject.other | Von Willebrand Disease | |
dc.subject.other | prophylaxis | |
dc.subject.other | Hemophilia | |
dc.subject.other | epistaxis | |
dc.subject.other | bleeding episodes | |
dc.title | Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/172819/1/hae14550.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/172819/2/hae14550_am.pdf | |
dc.identifier.doi | 10.1111/hae.14550 | |
dc.identifier.source | Haemophilia | |
dc.identifier.citedreference | Fogarty H, Doherty D, O’donnell JS. New developments in von Willebrand disease. Br J Haematol. 2020; 191 ( 3 ): 329 - 339. https://doi.org/10.1111/bjh.16681 | |
dc.identifier.citedreference | Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate P in inherited von Willebrand’s disease: a cohort study on 100 Italian patients. Multicenter Study. Haematologica. 2007; 92 ( 7 ): 944 - 951. | |
dc.identifier.citedreference | Holm E, Carlsson KS, Lövdahl S, Lail AE, Abshire TC, Berntorp E. Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network. Haemophilia. 2018; 24 ( 4 ): 628 - 633. https://doi.org/10.1111/hae.13473 | |
dc.identifier.citedreference | Abshire TC, Federici AB, Alvárez MT, et al. Prophylaxis in severe forms of von Willebrand’s disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Multicenter Study Research Support, Non-U.S. Gov’t. Haemophilia. 2013; 19 ( 1 ): 76 - 81. https://doi.org/10.1111/j.1365-2516.2012.02916.x | |
dc.identifier.citedreference | Nowak-Gottl U, Krumpel A, Russo A, Jansen M. Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age—results of a prospective multicentre clinical study including recovery information. Clinical Trial, Phase II Multicenter Study. Haemophilia. 2013; 19 ( 6 ): 887 - 92. https://doi.org/10.1111/hae.12237 | |
dc.identifier.citedreference | Lillicrap D, Poon MC, Walker I, et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002; 87 ( 2 ): 224 - 230. | |
dc.identifier.citedreference | Khair K, Batty P, Riat R, et al. Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience Research Support, Non-U.S. Gov’t. Haemophilia. 2015; 21 ( 1 ): e44 - 50. https://doi.org/10.1111/hae.12497 | |
dc.identifier.citedreference | Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study Research Support, Non-U.S. Gov’t. Haemophilia. 2007; 13 Suppl 5: 15 - 24. https://doi.org/10.1111/j.1365-2516.2007.01573.x | |
dc.identifier.citedreference | Dunkley S, Baker RI, Pidcock M, et al. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand’s disease: a prospective multi-centre study Multicenter Study Research Support, Non-U.S. Gov’t. Haemophilia. 2010; 16 ( 4 ): 615 - 24. https://doi.org/10.1111/j.1365-2516.2010.02206.x | |
dc.identifier.citedreference | Castaman G, Coppola A, Zanon E, et al. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease Multicenter Study Research Support, Non-U.S. Gov’t. Haemophilia. 2013; 19 ( 1 ): 82 - 8. https://doi.org/10.1111/hae.12005 | |
dc.identifier.citedreference | Holm E, Abshire TC, Bowen J, et al. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. Clinical Trial Research Support, Non-U.S. Gov’t. Blood Coagul Fibrinolysis. 2015; 26 ( 4 ): 383 - 8. https://doi.org/10.1097/MBC.0000000000000257 | |
dc.identifier.citedreference | Federici AB, Barillari G, Zanon E, et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score Research Support, Non-U.S. Gov’t. Haemophilia. 2010; 16 ( 1 ): 101 - 10. https://doi.org/10.1111/j.1365-2516.2009.02088.x | |
dc.identifier.citedreference | Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007; 5 ( 6 ): 1115 - 1124. http://doi.org/10.1111/j.1538-7836.2007.02562.x | |
dc.identifier.citedreference | Berntorp E, Windyga J. Treatment and prevention of acute bleedings in von Willebrand disease—efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia. 2009; 15 ( 1 ): 122 - 130. http://doi.org/10.1111/j.1365-2516.2008.01901.x | |
dc.identifier.citedreference | Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis. 2005;16 Suppl 1:S23-6. https://doi.org/10.1097/01.mbc.0000167659.23262.18 | |
dc.identifier.citedreference | Peyvandi F, Castaman G, Gresele P, et al. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfus. 2019; 17 ( 5 ): 391 - 398. | |
dc.identifier.citedreference | Tosetto A, Badiee Z, Baghaipour M-R, et al. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study. J Thromb Haemost. 2020; 18 ( 9 ): 2145 - 2154. https://doi.org/10.1111/jth.14886 | |
dc.identifier.citedreference | Leebeek FWG, Eikenboom JCJ. Von Willebranda ™s disease N Engl J Med. 2016; 375 ( 21 ): 2067 - 2080. https://doi.org/10.1056/NEJMra1601561 | |
dc.identifier.citedreference | GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University; 2020. Available from gradepro.org | |
dc.identifier.citedreference | Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336 ( 7650 ): 924 - 926. https://doi.org/10.1136/bmj.39489.470347.AD | |
dc.identifier.citedreference | Core Team R ( 2020 ). R: A language and environment for statistical computing. R Foundation for Statistical Computing, URL https://www.R-project.org/. | |
dc.identifier.citedreference | Review Manager (RevMan). Version Version 5.3. 2014. | |
dc.identifier.citedreference | Sterne JAc, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355: i4919. https://doi.org/10.1136/bmj.i4919 | |
dc.identifier.citedreference | Sterne JAC, Savović J, Page MJ, Elbers RG, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019; 366: l4898. https://doi.org/10.1136/bmj.l4898 | |
dc.identifier.citedreference | Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700. https://doi.org/10.1136/bmj.b2700 | |
dc.identifier.citedreference | Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5 ( 1 ): 301 - 325. https://doi.org/10.1182/bloodadvances.2020003264 | |
dc.identifier.citedreference | De Wee EM, Mauser-Bunschoten EP, Van Der Bom JG, et al. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost. 2010; 8 ( 7 ): 1492 - 9. https://doi.org/10.1111/j.1538-7836.2010.03864.x | |
dc.identifier.citedreference | Xu Y, Deforest M, Grabell J, Hopman W, James P. Relative contributions of bleeding scores and iron status on health-related quality of life in von Willebrand disease: a cross-sectional study. Haemophilia. 2017; 23 ( 1 ): 115 - 121. https://doi.org/10.1111/hae.13062 | |
dc.identifier.citedreference | Van Galen KPM, Sanders YV, Vojinovic U, et al. Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. Haemophilia. 2015; 21 ( 3 ): e185 - 92. https://doi.org/10.1111/hae.12670 | |
dc.identifier.citedreference | Govorov I, Ekelund L, Chaireti R, et al. Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand’s disease. Exp Ther Med. 2016; 11 ( 5 ): 1923 - 1929. https://doi.org/10.3892/etm.2016.3144 | |
dc.identifier.citedreference | Byams VR, Kouides PA, Kulkarni R, et al. Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia. 2011; 17 Suppl 1(0 1): 6 - 13. https://doi.org/10.1111/j.1365-2516.2011.02558.x | |
dc.identifier.citedreference | De Wee E, Knol H, Mauser-Bunschoten E, Van Der Bom J, et al. Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. Thromb Haemost. 2011; 106 ( 5 ): 885 - 92. https://doi.org/10.1160/th11-03-0180 | |
dc.identifier.citedreference | Castaman G, Federici AB, Tosetto A, et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost. 2012; 10 ( 4 ): 632 - 8. https://doi.org/10.1111/j.1538-7836.2012.04661.x | |
dc.identifier.citedreference | Biguzzi E, Siboni SM, Peyvandi F. How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease. Blood. 2020; 136 ( 10 ): 1125 - 1133. https://doi.org/10.1182/blood.2019003702 | |
dc.identifier.citedreference | Sadler JE, Budde U, Eikenboom JCJ, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4 ( 10 ): 2103 - 2114. https://doi.org/10.1111/j.1538-7836.2006.02146.x | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.